News coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.2891023643487 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates (finance.yahoo.com)
- Adamis Pharmaceuticals (ADMP) Announces Earnings Results (americanbankingnews.com)
- Adamis Pharmaceuticals misses on revenue (seekingalpha.com)
- Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update (finance.yahoo.com)
- Adamis: 2Q Earnings Snapshot (finance.yahoo.com)
NASDAQ ADMP remained flat at $$3.25 during mid-day trading on Friday. 537,007 shares of the company traded hands, compared to its average volume of 656,420. Adamis Pharmaceuticals has a 52-week low of $2.35 and a 52-week high of $5.85. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.88 and a quick ratio of 1.57. The stock has a market capitalization of $108.52 million, a price-to-earnings ratio of -3.61 and a beta of 0.45.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.10). Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%. The business had revenue of $3.92 million during the quarter, compared to analysts’ expectations of $4.14 million. sell-side analysts anticipate that Adamis Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.
Several research firms have issued reports on ADMP. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. B. Riley raised their target price on shares of Adamis Pharmaceuticals to $7.50 and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. ValuEngine raised shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $7.00 target price on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 14th. Finally, Maxim Group raised their target price on shares of Adamis Pharmaceuticals to $13.00 and gave the stock a “buy” rating in a research report on Monday, July 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $8.40.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Further Reading: Marijuana Stocks
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.